Radiopharmaceutical Formulation and Preclinical Testing of (68)Ga-Labeled DOTA-MGS5 for the Regulatory Approval of a First Exploratory Clinical Trial

The new minigastrin analog DOTA-MGS5 is a promising new candidate for targeting cholecystokinin-2 receptor (CCK2R)-expressing tumors. To enable the clinical translation of PET/CT imaging using (68)Ga-labeled DOTA-MGS5, different quality and safety aspects need to be considered to comply with the reg...

Descripción completa

Detalles Bibliográficos
Autores principales: Hörmann, Anton A., Klingler, Maximilian, Rangger, Christine, Mair, Christian, Decristoforo, Clemens, Uprimny, Christian, Virgolini, Irene J., von Guggenberg, Elisabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235783/
https://www.ncbi.nlm.nih.gov/pubmed/34208516
http://dx.doi.org/10.3390/ph14060575

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235783/
https://www.ncbi.nlm.nih.gov/pubmed/34208516
http://dx.doi.org/10.3390/ph14060575

Ejemplares similares